News >

Dabrafenib/Trametinib Combination Approved for Advanced Melanoma

Silas Inman @silasinman
Published: Thursday, Jan 09, 2014

Dr. Richard Pazdur

Richard Pazdur, MD

The FDA has granted an accelerated approval to the combination of the MEK inhibitor trametinib (Mekinist) and the BRAF inhibitor dabrafenib (Tafinlar) as a treatment for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x